Clinical cancer research : an official journal of the American Association for Cancer Research

publication venue for

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib. 2020
Immunologic Correlates of the Abscopal Effect in a SMARCB1/INI1-negative Poorly Differentiated Chordoma after EZH2 Inhibition and Radiotherapy. 2019
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. 2015
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. 2008
Herbal/hormonal dietary supplement possibly associated with prostate cancer progression. 2008
EWS-CREB1: a recurrent variant fusion in clear cell sarcoma--association with gastrointestinal location and absence of melanocytic differentiation. 2006
Classic Kaposi's sarcoma associated with human herpesvirus 8 infection in a 13-year-old male: a case report. 2001
Clonal Hematopoiesis in Young Women Treated for Breast Cancer.. 29. 2023
Determinants of survival in HER2+ metastatic esophagogastric cancer. 2023
Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.. 29. 2023
Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer.. 29. 2023
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia. 2023
Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer. 2023
The Immunogenomic Landscape of Neuroendocrine Prostate Cancer. 2023
A multiparameter molecular classifier to predict response to neoadjuvant lapatinib plus trastuzumab without chemotherapy in HER2+ breast cancer. 2023
PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer.. 29. 2023
Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.. 29. 2023
Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors.. 28. 2022
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.. 28. 2022
MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma.. 28. 2022
Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer.. 28. 2022
Microsatellite Instability-High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles.. 28. 2022
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors.. 28. 2022
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.. 28. 2022
An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors.. 28. 2022
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.. 28. 2022
Ultrasmall Nanoparticle Delivery of Doxorubicin Improves Therapeutic Index for High-Grade Glioma.. 28. 2022
The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma.. 28. 2022
Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program.. 28. 2022
Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer.. 28. 2022
Randomized, double-blind, placebo-controlled phase 3 study of paclitaxel {plus minus} napabucasin in pretreated advanced gastric or gastroesophageal junction adenocarcinoma. 2022
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.. 28. 2022
Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab.. 28. 2022
A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma.. 28. 2022
Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia.. 28. 2022
Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors.. 28. 2022
Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis.. 28. 2022
Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma.. 28. 2022
Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia.. 28. 2022
The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial.. 28. 2022
Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer.. 28. 2022
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.. 27. 2021
Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care.. 27. 2021
A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop.. 27. 2021
Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia.. 27. 2021
Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.. 27. 2021
Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer.. 27. 2021
Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer.. 27. 2021
Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.. 27. 2021
Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in BRAF^V600E -Driven Papillary Thyroid Cancer Patients.. 27. 2021
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.. 27. 2021
CDKN2A Alterations and Response to Immunotherapy in Solid Tumors.. 27. 2021
Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion.. 27. 2021
Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection.. 27. 2021
Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes.. 27. 2021
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.. 27. 2021
Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways.. 27. 2021
Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms.. 27. 2021
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response.. 27. 2021
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study.. 27. 2021
Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.. 27. 2021
KRAS ^G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma.. 27. 2021
Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas.. 27. 2021
Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer.. 27. 2021
Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER⁺ Breast Cancer.. 27. 2021
The State of Melanoma: Emergent Challenges and Opportunities.. 27. 2021
The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas.. 27. 2020
The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer.. 27. 2020
Genomic Characterization of de novo Metastatic Breast Cancer.. 27. 2020
Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor.. 27. 2020
Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma.. 27. 2020
Characterization and Clinical Outcomes of DNA Mismatch Repair-deficient Small Bowel Adenocarcinoma.. 27. 2020
MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance.. 27. 2020
Similarities in Risk for COVID-19 and Cancer Disparities.. 27. 2020
Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer.. 27. 2020
Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma.. 26. 2020
Correction: Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases.. 26. 2020
Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation.. 26. 2020
PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.. 26. 2020
HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome.. 26. 2020
Molecular Engineering of Ultrasmall Silica Nanoparticle-Drug Conjugates as Lung Cancer Therapeutics.. 26. 2020
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.. 26. 2020
Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome.. 26. 2020
Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab.. 26. 2020
Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study.. 26. 2020
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).. 26. 2020
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era.. 26. 2020
Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.. 26. 2020
Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer.. 26. 2020
Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing.. 26. 2020
Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.. 26. 2020
Safety and Feasibility of PARP1/2 Imaging with ¹⁸F-PARPi in Patients with Head and Neck Cancer.. 26. 2020
Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression.. 26. 2020
Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer.. 26. 2020
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.. 26. 2020
A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.. 26. 2020
OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models.. 26. 2020
Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy.. 26. 2020
Computationally Derived Image Signature of Stromal Morphology Is Prognostic of Prostate Cancer Recurrence Following Prostatectomy in African American Patients.. 26. 2020
MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions.. 26. 2020
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.. 26. 2020
Targeted Brain Tumor Radiotherapy Using an Auger Emitter.. 26. 2020
The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype.. 26. 2020
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC.. 26. 2020
Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors.. 26. 2020
Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer.. 26. 2020
A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers.. 26. 2020
Racial Differences in the Association Between Luminal Master Regulator Gene Expression Levels and Breast Cancer Survival.. 26. 2020
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations.. 26. 2019
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies.. 26. 2019
Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer.. 26. 2019
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma.. 26. 2019
Coaltered Ras/B-raf and TP53 Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer.. 26. 2019
Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.. 26. 2019
Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma.. 26. 2019
Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma.. 26. 2019
Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma.. 26. 2019
Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model.. 26. 2019
Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach.. 25. 2019
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors.. 25. 2019
Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma.. 25. 2019
PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.. 25. 2019
Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel.. 25. 2019
The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance.. 25. 2019
Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.. 25. 2019
Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer.. 25. 2019
Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations.. 25. 2019
Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas.. 25. 2019
Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.. 25. 2019
Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation In Vivo.. 25. 2019
Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations.. 25. 2019
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer.. 25. 2019
TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer.. 25. 2019
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden.. 25. 2019
Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases.. 25. 2019
Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.. 25. 2019
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab.. 25. 2019
Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer.. 25. 2019
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF ^V600-mutated Metastatic Melanoma.. 25. 2019
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.. 25. 2019
Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter?. 25. 2019
SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance.. 25. 2018
Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers.. 25. 2018
Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism.. 25. 2018
A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers.. 25. 2018
Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.. 24. 2018
Residual Tumor Volume, Cell Volume Fraction, and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR Imaging.. 25. 2018
Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations.. 25. 2018
Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.. 25. 2018
Targeting an Autocrine Regulatory Loop in Cancer Stem-like Cells Impairs the Progression and Chemotherapy Resistance of Bladder Cancer.. 25. 2018
Retraction: NRH:Quinone Oxidoreductase 2-Deficient Mice Are Highly Susceptible to Radiation-induced B-Cell Lymphomas.. 24. 2018
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.. 25. 2018
Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.. 25. 2018
Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.. 25. 2018
Leveraging Bioorthogonal Click Chemistry to Improve ²²⁵Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma.. 25. 2018
PTEN Expression, Not Mutation Status in TSC1, TSC2, or mTOR, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial.. 25. 2018
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.. 25. 2018
Expression of AR-V7 and ARv^567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY.. 25. 2018
Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer.. 25. 2018
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. 25. 2018
A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer.. 25. 2018
Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma.. 25. 2018
Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors.. 25. 2018
PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact.. 24. 2018
Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial.. 24. 2018
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.. 24. 2018
Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer.. 24. 2018
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.. 24. 2018
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.. 25. 2018
Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling.. 24. 2018
ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer.. 25. 2018
Mast Cell Activation and KSHV Infection in Kaposi Sarcoma.. 24. 2018
Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.. 24. 2018
Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy.. 24. 2018
Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays.. 24. 2018
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.. 24. 2018
Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas.. 24. 2018
Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib.. 24. 2018
Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study.. 24. 2018
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.. 24. 2018
A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.. 24. 2018
Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.. 24. 2018
Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib.. 24. 2018
Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients.. 24. 2018
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance.. 24. 2018
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer.. 24. 2018
Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer.. 24. 2018
Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.. 24. 2018
A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER⁺/HER2^- Advanced Breast Cancer.. 24. 2018
Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.. 24. 2018
Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.. 24. 2018
Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP.. 24. 2018
Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma.. 24. 2018
Personalized RNA Medicine for Pancreatic Cancer.. 24. 2018
First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors.. 24. 2017
Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer.. 24. 2017
Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis.. 24. 2017
RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition.. 24. 2017
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer.. 24. 2017
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma.. 24. 2017
A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors.. 24. 2017
CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors.. 23. 2017
A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma.. 23. 2017
A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.. 23. 2017
Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors.. 24. 2017
Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.. 23. 2017
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.. 23. 2017
Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research.. 24. 2017
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.. 23. 2017
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.. 23. 2017
Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype.. 23. 2017
Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells.. 23. 2017
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.. 23. 2017
Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence.. 23. 2017
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.. 23. 2017
Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer.. 23. 2017
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.. 23. 2017
Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin.. 23. 2017
Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer.. 23. 2017
Perioperative COX-2 and β-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial.. 23. 2017
Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.. 23. 2017
In Vivo Detection of EGFRvIII in Glioblastoma via Perfusion Magnetic Resonance Imaging Signature Consistent with Deep Peritumoral Infiltration: The φ-Index.. 23. 2017
Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.. 23. 2017
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.. 23. 2017
Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.. 23. 2017
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.. 23. 2017
A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer.. 23. 2017
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.. 23. 2017
Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.. 23. 2017
The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas.. 23. 2017
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.. 23. 2017
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.. 23. 2017
Malignant Astrocytic Tumor Progression Potentiated by JAK-mediated Recruitment of Myeloid Cells.. 23. 2016
Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity.. 23. 2016
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.. 23. 2016
Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.. 23. 2016
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab.. 23. 2016
Noninvasive Measurement of mTORC1 Signaling with ⁸⁹Zr-Transferrin.. 23. 2016
Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib.. 23. 2016
Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2^pos DCIS Independent of Route: Results of Randomized Selection Design Trial.. 23. 2016
Predicting MEK Inhibitor Response in Lung Cancer: A Proper Signature Is Required.. 23. 2016
Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins.. 23. 2016
Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response.. 23. 2016
Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases.. 23. 2016
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma.. 22. 2016
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.. 23. 2016
A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors.. 23. 2016
Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy.. 23. 2016
TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.. 23. 2016
The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population.. 23. 2016
Prognostic Utility of a New mRNA Expression Signature of Gleason Score.. 23. 2016
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling.. 22. 2016
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.. 23. 2016
Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer.. 23. 2016
An Expression Signature as an Aid to the Histologic Classification of Non-Small Cell Lung Cancer.. 22. 2016
Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma.. 22. 2016
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.. 22. 2016
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.. 22. 2016
Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial.. 22. 2016
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.. 22. 2016
A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.. 23. 2016
Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.. 22. 2016
MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.. 22. 2016
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.. 22. 2016
The Genomic Landscape of Male Breast Cancers.. 22. 2016
Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research.. 22. 2016
A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).. 22. 2016
Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer.. 22. 2016
Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients.. 22. 2016
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.. 22. 2016
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.. 22. 2016
Role of NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex 4-Like 2 in Clear Cell Renal Cell Carcinoma.. 22. 2016
Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.. 22. 2016
A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases.. 22. 2016
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.. 22. 2016
Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer.. 22. 2015
Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study.. 21. 2015
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.. 22. 2015
Identification of a Novel Pathogenic Germline KDR Variant in Melanoma.. 22. 2015
Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.. 22. 2015
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.. 22. 2015
Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib.. 22. 2015
Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer.. 22. 2015
MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.. 22. 2015
Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.. 22. 2015
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.. 22. 2015
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.. 22. 2015
Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer.. 22. 2015
A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.. 22. 2015
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities.. 22. 2015
Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.. 21. 2015
Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma.. 21. 2015
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.. 21. 2015
SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial.. 21. 2015
Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models.. 21. 2015
A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis.. 21. 2015
Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.. 21. 2015
EGFR: The Paradigm of an Oncogene-Driven Lung Cancer.. 21. 2015
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.. 21. 2015
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.. 21. 2015
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019.. 21. 2015
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer.. 21. 2015
Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer.. 21. 2015
Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms.. 21. 2015
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.. 21. 2015
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.. 21. 2015
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate.. 21. 2015
Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.. 21. 2015
Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology.. 21. 2015
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.. 21. 2015
Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.. 21. 2014
Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors.. 21. 2014
A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors.. 21. 2014
MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.. 21. 2014
Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.. 21. 2014
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.. 21. 2014
Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.. 20. 2014
Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas: role of Th2-mediated biased Th17 function.. 20. 2014
A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.. 20. 2014
Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.. 20. 2014
Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer.. 20. 2014
Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.. 20. 2014
Evidence for molecular differences in prostate cancer between African American and Caucasian men.. 20. 2014
Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).. 20. 2014
CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance.. 20. 2014
Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy.. 20. 2014
Prostate MRI: evaluating tumor volume and apparent diffusion coefficient as surrogate biomarkers for predicting tumor Gleason score.. 20. 2014
Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.. 20. 2014
Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.. 20. 2014
Toward a drug development path that targets metastatic progression in osteosarcoma.. 20. 2014
Blocking and randomization to improve molecular biomarker discovery.. 20. 2014
Old drug new use--amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity.. 20. 2014
Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs.. 20. 2014
SPINK1 protein expression and prostate cancer progression.. 20. 2014
Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment.. 20. 2014
PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.. 20. 2014
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy.. 20. 2014
Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor.. 20. 2014
Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.. 20. 2014
Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG.. 20. 2014
Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission.. 20. 2014
High-resolution array CGH and gene expression profiling of alveolar soft part sarcoma.. 20. 2014
Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma.. 20. 2014
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.. 20. 2014
DNA methyltransferase inhibition reverses epigenetically embedded phenotypes in lung cancer preferentially affecting polycomb target genes.. 20. 2013
Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma.. 20. 2013
A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.. 20. 2013
Oncogenic function of SCCRO5/DCUN1D5 requires its Neddylation E3 activity and nuclear localization.. 20. 2013
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.. 20. 2013
The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo.. 19. 2013
Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer.. 19. 2013
Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein.. 19. 2013
AACR Cancer Progress Report 2013.. 19. 2013
Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.. 19. 2013
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.. 19. 2013
Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class.. 19. 2013
Relationships between LDH-A, lactate, and metastases in 4T1 breast tumors.. 19. 2013
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).. 19. 2013
A novel aldehyde dehydrogenase-3 activator (Alda-89) protects submandibular gland function from irradiation without accelerating tumor growth.. 19. 2013
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.. 19. 2013
Developing standards for breakthrough therapy designation in oncology.. 19. 2013
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.. 19. 2013
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.. 19. 2013
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.. 19. 2013
Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.. 19. 2013
Characteristics of lung cancers harboring NRAS mutations.. 19. 2013
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.. 19. 2013
Agonist antibodies to TNFR molecules that costimulate T and NK cells.. 19. 2013
Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types.. 19. 2013
Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.. 19. 2013
Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors.. 19. 2013
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.. 19. 2013
Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets.. 19. 2013
18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors.. 19. 2013
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.. 19. 2013
Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer.. 19. 2013
Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients.. 19. 2013
Personalized chemotherapy profiling using cancer cell lines from selectable mice.. 19. 2013
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.. 18. 2012
Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.. 18. 2012
Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer.. 18. 2012
A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission.. 18. 2012
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.. 18. 2012
Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.. 18. 2012
AACR Cancer Progress Report 2012.. 18. 2012
Integrin αvβ3-targeted IRDye 800CW near-infrared imaging of glioblastoma.. 18. 2012
Scatter spectroscopic imaging distinguishes between breast pathologies in tissues relevant to surgical margin assessment.. 18. 2012
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.. 18. 2012
EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors.. 18. 2012
New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment.. 18. 2012
The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials.. 18. 2012
A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors.. 18. 2012
Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer.. 18. 2012
A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.. 18. 2012
Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6.. 18. 2012
Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.. 18. 2012
The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.. 18. 2012
A replication study and genome-wide scan of single-nucleotide polymorphisms associated with pancreatic cancer risk and overall survival.. 18. 2012
Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.. 18. 2012
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.. 18. 2012
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma.. 18. 2012
IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.. 18. 2012
Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer.. 18. 2012
The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial.. 18. 2012
A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.. 18. 2012
Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.. 18. 2012
A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration.. 18. 2012
Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.. 18. 2012
18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy.. 18. 2012
A three-gene expression signature model for risk stratification of patients with neuroblastoma.. 18. 2012
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.. 18. 2012
Imaging: strategies, controversies, and opportunities.. 18. 2012
Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability.. 18. 2012
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.. 18. 2012
Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer.. 18. 2012
Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.. 18. 2012
Drug development: portals of discovery.. 18. 2012
EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.. 18. 2011
Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.. 18. 2011
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.. 18. 2011
Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer.. 18. 2011
Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics.. 17. 2011
TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo.. 17. 2011
A novel aldehyde dehydrogenase-3 activator leads to adult salivary stem cell enrichment in vivo.. 17. 2011
GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy.. 17. 2011
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.. 17. 2011
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.. 17. 2011
Metabolic imaging: a link between lactate dehydrogenase A, lactate, and tumor phenotype.. 17. 2011
Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.. 17. 2011
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.. 17. 2011
Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.. 17. 2011
p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905).. 17. 2011
Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept.. 17. 2011
MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin.. 17. 2011
Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens.. 17. 2011
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.. 17. 2011
Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.. 17. 2011
Activity of Sorafenib against desmoid tumor/deep fibromatosis.. 17. 2011
Therapeutic implications of the emerging molecular biology of uveal melanoma.. 17. 2011
Molecular classification of gastric cancer: a new paradigm.. 17. 2011
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies.. 17. 2011
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.. 17. 2011
Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas.. 17. 2011
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.. 17. 2011
Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors.. 17. 2011
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.. 17. 2011
Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo.. 17. 2011
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.. 17. 2011
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.. 17. 2011
Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence.. 17. 2011
Androgen receptor expression and breast cancer survival in postmenopausal women.. 17. 2011
Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas.. 17. 2011
A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors.. 17. 2011
Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.. 17. 2011
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.. 17. 2011
Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.. 17. 2011
Role and relevance of TrkB mutations and expression in non-small cell lung cancer.. 17. 2011
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.. 17. 2011
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.. 17. 2011
Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.. 17. 2011
The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance.. 16. 2010
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.. 17. 2010
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer.. 17. 2010
Benign mesenchymal stromal cells in human sarcomas.. 16. 2010
HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.. 17. 2010
Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer.. 16. 2010
Portable filter-based microdevice for detection and characterization of circulating tumor cells.. 16. 2010
Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.. 16. 2010
Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study.. 16. 2010
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.. 16. 2010
Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.. 16. 2010
Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.. 16. 2010
The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder.. 16. 2010
Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.. 16. 2010
Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.. 16. 2010
Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F.. 16. 2010
A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development.. 16. 2010
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.. 16. 2010
Susceptibility loci associated with prostate cancer progression and mortality.. 16. 2010
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.. 16. 2010
A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.. 16. 2010
Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494.. 16. 2010
In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.. 16. 2010
Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.. 16. 2010
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.. 16. 2010
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.. 16. 2010
A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.. 16. 2010
A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.. 16. 2010
Melanoma MicroRNA signature predicts post-recurrence survival.. 16. 2010
Testing clonal relatedness of tumors using array comparative genomic hybridization: a statistical challenge.. 16. 2010
Frequent downregulation of miR-34 family in human ovarian cancers.. 16. 2010
High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.. 16. 2010
Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.. 16. 2010
Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report.. 16. 2010
Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation.. 16. 2010
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.. 16. 2010
Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.. 16. 2009
Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer.. 16. 2009
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.. 15. 2009
KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.. 15. 2009
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.. 15. 2009
Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors.. 15. 2009
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.. 15. 2009
Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study.. 15. 2009
Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.. 15. 2009
Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance.. 15. 2009
Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells.. 15. 2009
Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer.. 15. 2009
Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer.. 15. 2009
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival.. 15. 2009
Translocator protein blockade reduces prostate tumor growth.. 15. 2009
Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer.. 15. 2009
Interaction of molecular markers and physical activity on mortality in patients with colon cancer.. 15. 2009
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody.. 15. 2009
Integration of molecular profiling into the lung cancer clinic.. 15. 2009
Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers.. 15. 2009
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.. 15. 2009
PIK3CA mutation associates with improved outcome in breast cancer.. 15. 2009
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.. 15. 2009
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.. 15. 2009
Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training.. 15. 2009
Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.. 15. 2009
GAB2 amplifications refine molecular classification of melanoma.. 15. 2009
FOXA1 is a potential oncogene in anaplastic thyroid carcinoma.. 15. 2009
Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene.. 15. 2009
Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles.. 15. 2009
A phase I trial of enzastaurin in patients with recurrent gliomas.. 15. 2009
Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.. 15. 2009
Prognostic value of Akt-1 in human prostate cancer: a computerized quantitative assessment with quantum dot technology.. 15. 2009
Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.. 15. 2009
FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.. 15. 2009
Phosphorylated 4E-BP1 is associated with poor survival in melanoma.. 15. 2009
Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma.. 15. 2009
Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination.. 15. 2009
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.. 15. 2009
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer.. 15. 2009
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells.. 15. 2009
p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803.. 15. 2009
NRH:quinone oxidoreductase 2-deficient mice are highly susceptible to radiation-induced B-cell lymphomas.. 15. 2009
A simple and accurate model for prediction of cancer-specific mortality in patients treated with surgery for primary penile squamous cell carcinoma.. 15. 2009
Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck.. 15. 2009
Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade.. 15. 2009
An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer.. 15. 2009
Imaging intratumoral convection: pressure-dependent enhancement in chemotherapeutic delivery to solid tumors.. 15. 2009
A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients.. 14. 2008
Neuropilin-2-mediated tumor growth and angiogenesis in pancreatic adenocarcinoma.. 14. 2008
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.. 14. 2008
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.. 14. 2008
Cancer-related axonogenesis and neurogenesis in prostate cancer.. 14. 2008
Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.. 14. 2008
Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt.. 14. 2008
Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer.. 14. 2008
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.. 14. 2008
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.. 14. 2008
Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma.. 14. 2008
SCCRO (DCUN1D1) induces extracellular matrix invasion by activating matrix metalloproteinase 2.. 14. 2008
A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.. 14. 2008
A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer.. 14. 2008
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.. 14. 2008
CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer.. 14. 2008
Deletions of CDKN2C in multiple myeloma: biological and clinical implications.. 14. 2008
Shedding of distinct cryptic collagen epitope (HU177) in sera of melanoma patients.. 14. 2008
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.. 14. 2008
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival.. 14. 2008
The Translational Research Working Group developmental pathway for image-based assessment modalities.. 14. 2008
The Translational Research Working Group developmental pathway for interventive devices.. 14. 2008
Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo.. 14. 2008
A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer.. 14. 2008
Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.. 14. 2008
The Translational Research Working Group developmental pathways: introduction and overview.. 14. 2008
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.. 14. 2008
Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183.. 14. 2008
The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing.. 14. 2008
Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers.. 14. 2008
Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.. 14. 2008
ECSA/DPPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer.. 14. 2008
HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma.. 14. 2008
Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy.. 14. 2008
Molecular characterization of pediatric gastrointestinal stromal tumors.. 14. 2008
Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.. 14. 2008
Pilot randomized phase II study of celecoxib in oral premalignant lesions.. 14. 2008
Escherichia coli Nissle 1917 facilitates tumor detection by positron emission tomography and optical imaging.. 14. 2008
Prognostic value of body mass index in locally advanced breast cancer.. 14. 2008
Sensitivity of squamous cell carcinoma lymph node metastases to herpes oncolytic therapy.. 14. 2008
Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer.. 14. 2008
Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer.. 14. 2008
Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas.. 14. 2008
Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.. 14. 2008
Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples.. 14. 2008
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.. 14. 2008
Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.. 13. 2007
Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.. 13. 2007
A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.. 13. 2007
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.. 13. 2007
Novel markers of subclinical disease for Ewing family tumors from gene expression profiling.. 13. 2007
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.. 13. 2007
Nerve-sparing therapy with oncolytic herpes virus for cancers with neural invasion.. 13. 2007
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.. 13. 2007
Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine.. 13. 2007
Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma.. 13. 2007
Inhibition of Jun NH2-terminal kinases suppresses the growth of experimental head and neck squamous cell carcinoma.. 13. 2007
Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors.. 13. 2007
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.. 13. 2007
Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer.. 13. 2007
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.. 13. 2007
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.. 13. 2007
Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?. 13. 2007
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.. 13. 2007
Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.. 13. 2007
Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.. 13. 2007
Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.. 13. 2007
Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy.. 13. 2007
BRCA mutations in women with ductal carcinoma in situ.. 13. 2007
Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma.. 13. 2007
Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer.. 13. 2007
Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.. 13. 2007
A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183.. 13. 2007
A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.. 13. 2007
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.. 13. 2007
In vivo 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors.. 13. 2007
A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer.. 13. 2007
Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.. 13. 2007
A 10-gene classifier for distinguishing head and neck squamous cell carcinoma and lung squamous cell carcinoma.. 13. 2007
Disruption of endothelial cell interactions with the novel HU177 cryptic collagen epitope inhibits angiogenesis.. 13. 2007
Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.. 13. 2007
A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.. 13. 2007
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors.. 13. 2007
Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2.. 13. 2007
The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate.. 13. 2007
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.. 13. 2007
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.. 13. 2007
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors.. 13. 2007
Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors.. 13. 2007
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.. 13. 2007
Relaxin promotes prostate cancer progression.. 13. 2007
The association between measures of progression and survival in castrate-metastatic prostate cancer.. 13. 2007
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs.. 13. 2007
Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system.. 13. 2007
Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer.. 13. 2007
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.. 13. 2007
Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.. 13. 2007
Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease.. 12. 2006
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.. 12. 2006
Rapid androgen cycling as treatment for patients with prostate cancer.. 12. 2006
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.. 12. 2006
Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes.. 12. 2006
Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma.. 12. 2006
Nomograms provide improved accuracy for predicting survival after radical cystectomy.. 12. 2006
SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation.. 12. 2006
Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer.. 12. 2006
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.. 12. 2006
Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors.. 12. 2006
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.. 12. 2006
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study.. 12. 2006
GROalpha is highly expressed in adenocarcinoma of the colon and down-regulates fibulin-1.. 12. 2006
Pharmacokinetics and toxicity of weekly docetaxel in older patients.. 12. 2006
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.. 12. 2006
Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma.. 12. 2006
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.. 12. 2006
Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors.. 12. 2006
YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.. 12. 2006
Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains.. 12. 2006
Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma.. 12. 2006
Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.. 12. 2006
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.. 12. 2006
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.. 12. 2006
Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.. 12. 2006
An in vivo platform for translational drug development in pancreatic cancer.. 12. 2006
Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice.. 12. 2006
The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.. 12. 2006
A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors.. 12. 2006
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival.. 12. 2006
c-Met ectodomain shedding rate correlates with malignant potential.. 12. 2006
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.. 12. 2006
Novel blood biomarkers of human urinary bladder cancer.. 12. 2006
Preferential nuclear and cytoplasmic NY-BR-1 protein expression in primary breast cancer and lymph node metastases.. 12. 2006
Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.. 12. 2006
Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.. 12. 2006
Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study.. 12. 2006
Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.. 12. 2006
Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity.. 12. 2006
The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer.. 12. 2006
An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers.. 12. 2006
A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.. 12. 2006
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.. 12. 2006
Stress hormone-mediated invasion of ovarian cancer cells.. 12. 2006
Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer.. 12. 2006
Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity.. 12. 2006
Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.. 11. 2005
Natural killer cells license dendritic cell cross-presentation of B lymphoma cell--associated antigens.. 11. 2005
Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy.. 11. 2005
Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.. 11. 2005
In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent.. 11. 2005
The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.. 11. 2005
Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer.. 11. 2005
Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles.. 11. 2005
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.. 11. 2005
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer.. 11. 2005
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.. 11. 2005
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia.. 11. 2005
Effects of exercise training on antitumor efficacy of doxorubicin in MDA-MB-231 breast cancer xenografts.. 11. 2005
Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.. 11. 2005
Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma.. 11. 2005
Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.. 11. 2005
Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies.. 11. 2005
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.. 11. 2005
Breast cancer molecular subtypes respond differently to preoperative chemotherapy.. 11. 2005
Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers.. 11. 2005
Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.. 11. 2005
PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation.. 11. 2005
Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy.. 11. 2005
2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy.. 11. 2005
Enhanced nectin-1 expression and herpes oncolytic sensitivity in highly migratory and invasive carcinoma.. 11. 2005
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.. 11. 2005
Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer.. 11. 2005
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.. 11. 2005
CD44 expression is associated with increased survival in node-negative invasive breast carcinoma.. 11. 2005
Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes.. 11. 2005
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy.. 11. 2005
Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy.. 11. 2005
Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.. 11. 2005
Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.. 11. 2005
Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma.. 11. 2005
Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma.. 11. 2005
Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer.. 11. 2005
Reg IV: a promising marker of hormone refractory metastatic prostate cancer.. 11. 2005
Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel.. 11. 2005
An 19F magnetic resonance-based in vivo assay of solid tumor methotrexate resistance: proof of principle.. 11. 2005
Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.. 11. 2005
Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma.. 11. 2005
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.. 11. 2005
CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma.. 11. 2005
Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.. 11. 2005
Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer.. 10. 2004
Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1.. 10. 2004
Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.. 10. 2004
The radioisotope contributes significantly to the activity of radioimmunotherapy.. 10. 2004
Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients.. 10. 2004
In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity.. 10. 2004
Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.. 10. 2004
A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.. 10. 2004
High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence.. 10. 2004
NY-ESO-1 expression and immunogenicity in esophageal cancer.. 10. 2004
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.. 10. 2004
Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin.. 10. 2004
p53 expression as a prognostic marker in inflammatory breast cancer.. 10. 2004
Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung.. 10. 2004
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.. 10. 2004
The role of hyperthermia in regional alkylating agent chemotherapy.. 10. 2004
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.. 10. 2004
A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.. 10. 2004
A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor.. 10. 2004
Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.. 10. 2004
Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.. 10. 2004
Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12.. 10. 2004
Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer.. 10. 2004
Neutral endopeptidase protein expression and prognosis in localized prostate cancer.. 10. 2004
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.. 10. 2004
The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.. 10. 2004
Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site.. 10. 2004
Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study.. 10. 2004
Reduced lecithin: retinol acyltransferase expression correlates with increased pathologic tumor stage in bladder cancer.. 10. 2004
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.. 10. 2004
BRCA mutations and risk of prostate cancer in Ashkenazi Jews.. 10. 2004
Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: a potential target to increase anticancer activity.. 10. 2004
Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial.. 10. 2004
Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin.. 10. 2004
Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy.. 10. 2004
Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571).. 10. 2004
Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression.. 10. 2004
Inhibition of orthotopic human bladder tumor growth by lentiviral gene transfer of endostatin.. 10. 2004
Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II).. 10. 2004
Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia.. 10. 2004
Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis.. 10. 2004
Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.. 10. 2004
Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin.. 10. 2004
Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma.. 10. 2004
Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase.. 10. 2004
Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12.. 10. 2004
Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice.. 10. 2004
Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer.. 10. 2004
Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro.. 9. 2003
Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.. 9. 2003
Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.. 9. 2003
Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies.. 9. 2003
Differential expression of the enzyme that esterifies retinol, lecithin:retinol acyltransferase, in subtypes of human renal cancer and normal kidney.. 9. 2003
Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer.. 9. 2003
Metabolic response of the CWR22 prostate tumor xenograft after 20 Gy of radiation studied by 1H spectroscopic imaging.. 9. 2003
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.. 9. 2003
A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.. 9. 2003
Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.. 9. 2003
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.. 9. 2003
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.. 9. 2003
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index.. 9. 2003
Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors.. 9. 2003
Microsomal prostaglandin E synthase-1 is overexpressed in head and neck squamous cell carcinoma.. 9. 2003
Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.. 9. 2003
A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer.. 9. 2003
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.. 9. 2003
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.. 9. 2003
10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer.. 9. 2003
Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.. 9. 2003
Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.. 9. 2003
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.. 9. 2003
The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue.. 9. 2003
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.. 9. 2003
Classification of follicular thyroid tumors by molecular signature: results of gene profiling.. 9. 2003
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.. 9. 2003
Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial.. 9. 2003
Phase I study of anticolon cancer humanized antibody A33.. 9. 2003
Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer.. 9. 2003
High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer.. 9. 2003
Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples.. 9. 2003
European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.. 9. 2003
P7 antigen expression in human breast cancer.. 9. 2003
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.. 8. 2002
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.. 8. 2002
Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers.. 8. 2002
Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.. 8. 2002
Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis.. 8. 2002
Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.. 8. 2002
Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women.. 8. 2002
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.. 8. 2002
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.. 8. 2002
Quantifying the amount of variation in survival explained by prostate-specific antigen.. 8. 2002
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.. 8. 2002
Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.. 8. 2002
Synergistic activation of the androgen receptor by bombesin and low-dose androgen.. 8. 2002
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.. 8. 2002
Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma.. 8. 2002
T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.. 8. 2002
Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma.. 8. 2002
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.. 8. 2002
Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.. 8. 2002
Automated electrorotation to reveal dielectric variations related to HER-2/neu overexpression in MCF-7 sublines.. 8. 2002
Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study.. 8. 2002
Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460.. 8. 2002
Picking the winners in a sea of plenty.. 8. 2002
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.. 8. 2002
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.. 8. 2002
Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.. 8. 2002
Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.. 7. 2001
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.. 7. 2001
Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer.. 7. 2001
Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.. 7. 2001
Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases.. 7. 2001
Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.. 7. 2001
Experimental therapeutics with a new 10-deazaaminopterin in human mesothelioma: further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums.. 7. 2001
Lack of correlation of functional scintigraphy with (99m)technetium-methoxyisobutylisonitrile with histological necrosis following induction chemotherapy or measures of P-glycoprotein expression in high-grade osteosarcoma.. 7. 2001
The T cell death knell: immune-mediated tumor death in renal cell carcinoma.. 7. 2001
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.. 7. 2001
Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.. 7. 2001
Genetic alterations in tp53 in recurrent urothelial cancer: a longitudinal study.. 7. 2001
HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer.. 7. 2001
Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer.. 7. 2001
Biological behavior of human breast cancer micrometastases.. 7. 2001
Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients.. 7. 2001
Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.. 7. 2001
Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients.. 7. 2001
Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR.. 7. 2001
Collocation of androgen receptor gene mutations in prostate cancer.. 7. 2001
Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.. 7. 2001
Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma.. 7. 2001
Reduction of paclitaxel-induced peripheral neuropathy with glutamine.. 7. 2001
Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells.. 7. 2001
Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.. 7. 2001
Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.. 7. 2001
Multiple high-grade bronchial dysplasia and squamous cell carcinoma: concordant and discordant mutations.. 7. 2001
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.. 6. 2000
Expression of metastases-associated genes in cervical cancers resected in the proliferative and secretory phases of the menstrual cycle.. 6. 2000
Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma.. 6. 2000
Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment.. 6. 2000
Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients.. 6. 2000
Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin.. 6. 2000
Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma.. 6. 2000
Presence of human papilloma virus in tumor tissue from children with retinoblastoma: an alternative mechanism for tumor development.. 6. 2000
Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo.. 6. 2000
Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.. 6. 2000
Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma.. 6. 2000
Monoclonality of multifocal myxoid liposarcoma: confirmation by analysis of TLS-CHOP or EWS-CHOP rearrangements.. 6. 2000
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.. 6. 2000
Imaging and phase I study of 111In- and 90Y-labeled anti-LewisY monoclonal antibody B3.. 6. 2000
Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550).. 6. 2000
Methylation of the neutral endopeptidase gene promoter in human prostate cancers.. 6. 2000
Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone.. 6. 2000
Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.. 6. 2000
The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.. 6. 2000
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.. 6. 2000
Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.. 6. 2000
The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer.. 6. 2000
Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia.. 6. 2000
Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.. 6. 2000
Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway.. 6. 2000
Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.. 5. 1999
Different patterns of angiogenesis in sarcomas and carcinomas.. 5. 1999
Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer.. 5. 1999
Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model.. 5. 1999
Simplified production of a recombinant human angiostatin derivative that suppresses intracerebral glial tumor growth.. 5. 1999
A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.. 5. 1999
Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer.. 5. 1999
Prostate-specific membrane antigen is produced in tumor-associated neovasculature.. 5. 1999
Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs.. 5. 1999
Association between molecular detection of GAGE and survival in patients with malignant melanoma: a retrospective cohort study.. 5. 1999
Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.. 5. 1999
Expression of dominant-negative Ikaros isoforms in T-cell acute lymphoblastic leukemia.. 5. 1999
Inactivation of the p53 pathway in prostate cancer: impact on tumor progression.. 5. 1999
Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas.. 5. 1999
Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-alpha-2a.. 5. 1999
Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin.. 5. 1999
Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer.. 5. 1999
Mechanisms of apoptosis in T cells from patients with renal cell carcinoma.. 5. 1999
Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.. 5. 1999
Mechanisms of methotrexate resistance in osteosarcoma.. 5. 1999
Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.. 5. 1999
Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies.. 5. 1999
Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice.. 4. 1998
A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.. 4. 1998
Antileukemia activity of a natural killer cell line against human leukemias.. 4. 1998
Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers.. 4. 1998
Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells.. 4. 1998
Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma.. 4. 1998
Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma.. 4. 1998
Overexpression of cyclin D1 is associated with poor prognosis in extremity soft-tissue sarcomas.. 4. 1998
Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma.. 4. 1998
UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner.. 4. 1998
Elevated expression of caveolin is associated with prostate and breast cancer.. 4. 1998
Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity.. 4. 1998
A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index.. 4. 1998
Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.. 4. 1998
p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer.. 4. 1998
In vivo native cellular fluorescence and histological characteristics of head and neck cancer.. 4. 1998
Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.. 4. 1998
Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer.. 4. 1998
Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.. 4. 1998
Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.. 4. 1998
Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma.. 4. 1998
Antitumor activity of actinonin in vitro and in vivo.. 4. 1998
Expression of cyclin D1, but not cyclins E and A, is related to progression in bilharzial bladder cancer.. 3. 1997
High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.. 3. 1997
A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.. 3. 1997
UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II)independent of p53 status.. 3. 1997
Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma.. 3. 1997
Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells.. 3. 1997
Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer.. 3. 1997
Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.. 3. 1997
Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer.. 3. 1997
Distribution of radiolabeled monoclonal antibody MX35 F(ab')2 in tissue samples by storage phosphor screen image analysis: evaluation of antibody localization to micrometastatic disease in epithelial ovarian cancer.. 3. 1997
Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases.. 3. 1997
Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma.. 3. 1997
A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin.. 3. 1997
Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.. 3. 1997
Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi.. 3. 1997
Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.. 3. 1997
A phase I trial of a new recombinant human beta-interferon (BG9015) for the treatment of patients with recurrent gliomas.. 3. 1997
Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas.. 3. 1997
Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.. 3. 1997
Basic fibroblast growth factor confers growth inhibition and mitogen-activated protein kinase activation in human breast cancer cells.. 3. 1997
K-ras mutation in adenomas and carcinomas of the ampulla of vater.. 3. 1997
High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer.. 2. 1996
Prognostic value of TrkA protein detection by monoclonal antibody 5C3 in neuroblastoma.. 2. 1996
Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid.. 2. 1996
Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.. 2. 1996
Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical study.. 2. 1996
Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen.. 2. 1996
Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid.. 2. 1996
Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression.. 2. 1996
Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma.. 2. 1996
Block of c-myc expression by antisense oligonucleotides inhibits proliferation of human thyroid carcinoma cell lines.. 2. 1996
Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.. 1. 1995
Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma.. 1. 1995
Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer.. 1. 1995
Association of p53 mutations with metastatic prostate cancer.. 1. 1995
Elimination of human leukemia by monoclonal antibodies in an athymic nude mouse leukemia model.. 1. 1995
Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma.. 1. 1995
Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms.. 1. 1995
Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia.. 1. 1995
Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. 2021
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. 2021
Standardized Uptake Value Illuminates Tumor Inflammation and Treatment Response. 2021
Combined Inhibition of Gα_q and MEK Enhances Therapeutic Efficacy in Uveal Melanoma. 2020
Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer. 2020
Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer. 2020
A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy. 2020
PD-1 Blockade in Chinese versus Western Patients with Melanoma. 2020
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. 2020
TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly? 2020
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. 2020
Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer. 2019
Today's Special on the Anticancer Menu: Immunomodulation by Antifolates. 2019
Exercise as a Candidate Antitumor Strategy: A Window into the Future. 2019
Retinoblastoma Loss in Cancer: Casting a Wider Net. 2019
First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors. 2019
About Face: Molecular Aberrations in Head and Neck Mucosal Melanomas. 2019
Virus, Vessel, Victory: A Novel Approach to Tumor Killing. 2018
First CAR to Pass the Road Test: Tisagenlecleucel's Drive to FDA Approval. 2018
Bigger Is Not Always Better: Tumor Size and Prognosis in Advanced Melanoma. 2018
Genotyping Natural Killer Immune Checkpoints to Discover Biomarkers of Response. 2017
Profiling Non-Small Cell Lung Cancer: From Tumor to Blood. 2015
CCR 20th Anniversary Commentary: Immune-Related Response Criteria--Capturing Clinical Activity in Immuno-Oncology. 2015
Next-Generation Sequencing: Targeting Targeted Therapies. 2015
Coamplification and cooperation: toward identifying biologically relevant oncogenes. 2013
Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas? 2012
The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime? 2012
Inclusion of patients with brain metastases in phase I trials: an unmet need. 2011
Telomeres: the long and short of developing non-Hodgkin lymphoma. 2009
Tumor hypoxia imaging. 2006
Clinical Significance of AR-V567es in Prostate Cancer-Response. 2019
RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer-Response. 2015
Pharmacogenomic modeling in pancreatic cancer—response. 2015
Reliable and effective diagnostics are keys to accelerating personalized cancer medicine and transforming cancer care: a policy statement from the american association for cancer research. 2014
Quantitative analysis of circulating tumor cells as a survival predictor in metastatic castration-resistant prostate cancer: missing parts in a superb study. 2009
Prediction of cancer relapse after prostatectomy: use the postoperative nomogram. 2009
Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. 2007
The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects. 2006
Correspondence re: C. G. Ferreira et al., Apoptosis: target of cancer therapy. Clin. Cancer Res., 8: 2024-2034, 2002. 2003
Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008. 2009
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. 2009
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. 2007
Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference. 2006
Innovations and challenges in renal cancer: consensus statement from the first international conference. 2004
Novel agents in the treatment of lung cancer: conference summary statement. 2004
Testing of new agents in childhood cancer preclinical models: meeting summary. 2002
Tumor receptor imaging: proceedings of the National Cancer Institute workshop, review of current work, and prospective for further investigations. 1995
A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid).. 29. 2023
Shedding Light on PARP Inhibitor Response through Functional Imaging.. 29. 2023
Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti-PD-1-Resistant Advanced Melanoma.. 29. 2023
Introducing a New Series: Immunotherapy Facts and Hopes.. 24. 2018
Positron emission tomography-based molecular imaging in human cancer: exploring the link between hypoxia and accelerated glucose metabolism.. 10. 2004
Cyclooxygenase inhibition as a target for prevention of tobacco-related cancers.. 10. 2004
Of peptides and peptidases: the role of cell surface peptidases in cancer.. 9. 2003
Molecular imaging in oncology: the diagnostic imaging "revolution".. 6. 2000
Discodermolide: just another microtubule-stabilizing agent? No! A lesson in synergy.. 6. 2000
Facts and Hopes in Immunotherapy of Pancreatic Cancer. 2022
Progresses Toward Precision Medicine in RET-altered Solid Tumors. 2020
Radiation-induced Adaptive Response: New Potential for Cancer Treatment. 2020
Immune Activation in Mismatch Repair-Deficient Carcinogenesis: More Than Just Mutational Rate. 2019
Immunotherapy of Melanoma: Facts and Hopes. 2019
Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis. 2019
The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer. 2018
Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality? 2017
Immunotherapy of Lymphoma and Myeloma: Facts and Hopes. 2017
Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers. 2017
Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders. 2017
The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target. 2016
Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker. 2016
Emerging Opportunities and Challenges in Cancer Immunotherapy. 2016
Molecular Pathways: Immunosuppressive Roles of IRE1α-XBP1 Signaling in Dendritic Cells of the Tumor Microenvironment. 2016
The Role of Neoadjuvant Trials in Drug Development for Solid Tumors. 2016
Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer. 2016
New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy. 2016
ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. 2015
Molecular Pathways: IDH2 Mutations-Co-opting Cellular Metabolism for Malignant Transformation. 2015
Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling. 2015
New strategies in glioblastoma: exploiting the new biology. 2015
Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. 2014
Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. 2014
A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer. 2014
Molecular pathways: CDK4 inhibitors for cancer therapy. 2014
Aggressive variants of castration-resistant prostate cancer. 2014
Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. 2014
Molecular pathways: HER3 targeted therapy. 2014
"Quitting smoking will benefit your health": the evolution of clinician messaging to encourage tobacco cessation. 2014
Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor. 2013
Molecular pathways: targeting MALT1 paracaspase activity in lymphoma. 2013
The winning formulation: the development of paclitaxel in pancreatic cancer. 2013
New strategies in prostate cancer: translating genomics into the clinic. 2012
Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. 2012
Circulating tumor cells as biomarkers in prostate cancer. 2011
Prognostic immune markers in non-small cell lung cancer. 2011
Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. 2010
New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK. 2010
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. 2009
Microtubule active agents: beyond the taxane frontier. 2008
Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. 2008
Tissue-based research in kidney cancer: current challenges and future directions. 2008
Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. 2008
Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma. 2007
Vascular endothelial growth factor trap in non small cell lung cancer. 2007
Imaging update: new windows, new views. 2007
The potential of antiangiogenic therapy in non-small cell lung cancer. 2007
Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing. 2007
Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. 2007
PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. 2007
Targeting von Hippel-Lindau pathway in renal cell carcinoma. 2006
Update on epidermal growth factor receptor mutations in non-small cell lung cancer. 2006
Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodeling. 2006
Mouse modeling in oncologic preclinical and translational research. 2006
Epidermal growth factor receptor mutation testing in the care of lung cancer patients. 2006
Activities and accomplishments of the cancer and leukemia group B genitourinary committee. 2006
The progress and promise of molecular imaging probes in oncologic drug development. 2005
Prostate cancer clinical trial end points: "RECIST"ing a step backwards. 2005
Cell death independent of caspases: a review. 2005
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. 2005
Bevacizumab for patients with metastatic renal cancer: an update. 2004
Debulking nephrectomy in metastatic renal cancer. 2004
Mammalian target of rapamycin inhibition. 2004
Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience. 2004
Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy. 2004
Tyrosine kinase inhibitors in renal cell carcinoma. 2004
The role of gefitinib in lung cancer treatment. 2004
Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. 2003
Epratuzumab: targeting B-cell malignancies through CD22. 2003
Soft tissue sarcomas of adults: state of the translational science. 2003
Apoptosis: target of cancer therapy. 2002
Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. 2001
Ceramide and the induction of apoptosis. 1996
Radioimmunotherapy of hematological cancer: problems and progress. 1995
The emerging role of paclitaxel in breast cancer therapy. 1995

VIVO Weill Cornell Medical College

Clinical cancer research : an official journal of the American Association for Cancer Research Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)